JOHANNESBURG, Sept 30 (Reuters) - South Africa's AspenPharmacare said on Monday it had agreed to a price of600 million pounds ($967 million) to buy thrombosis drugs and afactory from shareholder GlaxoSmithKline.
Aspen and Britain's Glaxo first announced the deal in June.